FDA Deems Angiomax sNDA "Not Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Bivalirudin supplemental application for patients undergoing percutaneous coronary intervention contained deficiencies in both the study methods and the analysis, FDA finds. Drug sponsor The Medicines Company plans to request a meeting with the agency.
You may also be interested in...
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
Angiomax “Not Approvable” For Acute Coronary Syndromes
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
Angiomax Gains Second Label Expansion For 2005
Supplement cleared Nov. 30 allows use of the anticoagulant bivalirudin in percutaneous coronary intervention patients at risk for heparin-induced thrombocytopenia or thrombosis syndrome.